{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(6)"],"submitter":["Chen GF"],"funding":["Humanity and Health Medical Group","Cheng Si-Yuan (China-International) Hepatitis Research Foundation"],"pubmed_abstract":["Background
Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions.Methods
A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate th"],"journal":["PloS one"],"pagination":["e0155934"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4898683"],"repository":["biostudies-literature"],"pubmed_title":["Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data."],"pmcid":["PMC4898683"],"pubmed_authors":["Jia JD","Wang GQ","Zhang YX","Wang C","Liu JL","Shang J","Han Y","Jia ZS","Wang XJ","Zhang WH","Ren H","Yang XX","Wong A","Zhuang H","Hou JL","Li B","Shao Q","Wu V","Wei L","Cheng J","Duan ZP","Ji D","Wang JP","Chen J","Li F","Wang YD","Chen GF","Xie Q","Niu XX","Fu QC","Lu LG","Fan JG","Lau G","Dou XG","Du N"],"additional_accession":[]},"is_claimable":false,"name":"Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.","description":"Background
Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions.Methods
A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate th","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2025-05-29T19:42:36.538Z","creation":"2019-03-26T22:51:58Z"},"accession":"S-EPMC4898683","cross_references":{"pubmed":["27276081"],"doi":["10.1371/journal.pone.0155934"]}}